Red blood cell modifiers for Plasmodium falciparum growth in sickle cell disease erythrocytes
Red blood cell modifiers for Plasmodium falciparum growth in sickle cell disease erythrocytes
批准号:
10055317
负责人:
Natasha Marie Bernadette Archer
金额:
$16.94万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-08-01 至 2025-04-30
关键词:
Advisory CommitteesAffectAfricaAreaAwardBindingBiological AssayBostonCell CycleCell Cycle StageCellsCellular AssayCellular biologyCessation of lifeChildCommunitiesCoupledDNA biosynthesisDataDigestionDiseaseDisease OutcomeEpidemiologyErythrocytesFalciparum MalariaFetal HemoglobinFoundationsGenesGeneticGenetic PolymorphismGenotypeGoalsGrowthHemoglobinHemoglobin CHemoglobin F DiseaseHemoglobin SC DiseaseHemoglobinopathiesHeterozygoteHypoxiaIn VitroIndividualInfectionInheritedInstitutionIntegration Host FactorsInternationalLeadershipMalariaMapsMathematicsMediatingMentorsModelingMolecularMorbidity - disease rateMutateMutationNewborn InfantOutcomeOxygenParasitemiaParasitesPathologyPatientsPediatric HematologistPediatric HematologyPediatric HospitalsPhenotypePhysiciansPlasmodium falciparumPloidiesPoint MutationPopulationPositioning AttributeProliferatingPublic Health SchoolsResearchResearch PersonnelResearch ProposalsResearch TrainingResistanceRoleScientistSeveritiesSickle Cell AnemiaSickle HemoglobinStagingStructureSubgroupTestingThalassemiaTherapeuticTrainingTransgenic OrganismsUmbilical Cord BloodVirulenceVirulentWorkalpha-Thalassemiacareercell typeclinically relevantcomorbidityexperiencegenome sequencinghemoglobin AAimprovedin vivo Modelmalaria infectionmathematical modelmortalitynovelparasite genomepolymerizationprematureprogramsresistant Plasmodium falciparumreverse geneticssicklingskillstherapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Sickle cell disease (SCD) is a deadly red blood cell (RBC) disorder estimated to affect over 300,000
newborns annually1. In SCD, mutated hemoglobin (HbS) polymerizes2 and causes RBCs to become sickle-
shaped. SCD remains prevalent because heterozygous carriers (HbAS) are partially resistance to Plasmodium
falciparum malaria3,4, which causes 400,000 deaths annually5. I recently identified HbS polymerization in low
oxygen (O2) as the main driver in HbAS resistance to P. falciparum6. This should suggest homozygous HbSS
confers greater resistance to malaria, but paradoxically, infected SCD individuals (HbSS) have increased
malaria morbidity and mortality7-9. I propose a novel hypothetical model of SCD and malaria interaction in
which RBC factors, like fetal hemoglobin (HbF), that create a RBC reservoir in which little to no HbS
polymerization occurs, may enable severe malaria. Using a variety of SCD RBC cell types, I will map and
model the in vitro growth dynamics of P. falciparum in SCD erythrocytes and identify RBC factors that influence
malaria infectivity within this population. This work is foundational in elucidating the molecular mechanisms
underlying the interaction between SCD and malaria, and is a major first step in identifying novel treatment
targets for severe malaria, SCD, and its comorbidities.
I am a pediatric hematologist co-mentored by Dr. Manoj Duraisingh and Dr. Caroline Buckee, both of
Harvard's T.H. Chan School of Public Health. My long-term goal is to become an independent physician-
scientist investigating the effect of the RBC host on malaria growth and to target such factors therapeutically.
My prior research experiences have allowed me to acquire the cellular biology skills to investigate in vitro
malaria growth. Through the critical mentored K08 award, I am now well positioned to acquire new skills in
mathematical modeling and parasite genetics to better understand the epidemiology of hemoglobinopathies in
malaria endemic regions, assess the impact of the introduction of RBC polymorphisms within communities,
and find potential therapeutic targets for children with SCD that become infected with malaria. The Boston
Children's Hospital and Harvard T.H. Chan School of Public Health are internationally recognized research
programs with a number of expert researchers in the areas of hemoglobinopathies, mathematical modeling,
and malaria. Boston Children's Hospital, my primary institution, has a distinguished record of training young
physician-scientists for leadership roles in pediatric hematology research. I have assembled an excellent
scientific advisory committee, consisting of Drs. Higgins, Goldberg, and Sankaran. Drs. Brugnara and Nathan,
will continue to serve as my career mentors and guide my research and training experiences. With the
structured mentoring, educational, and research plans detailed in this proposal, I will acquire the necessary
expertise to become a successful independent investigator with a focus on hemoglobinopathies and malaria.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Red blood cell modifiers for Plasmodium falciparum growth in sickle cell disease erythrocytes
-
批准号:10224189
-
项目类别:
-
资助金额:$16.79万
-
财政年份:2020
-
负责人:Natasha Marie Bernadette Archer
-
依托单位:
Red blood cell modifiers for Plasmodium falciparum growth in sickle cell disease erythrocytes
-
批准号:10404079
-
项目类别:
-
资助金额:$16.79万
-
财政年份:2020
-
负责人:Natasha Marie Bernadette Archer
-
依托单位:
Red blood cell modifiers for Plasmodium falciparum growth in sickle cell disease erythrocytes
-
批准号:10610899
-
项目类别:
-
资助金额:$16.79万
-
财政年份:2020
-
负责人:Natasha Marie Bernadette Archer
-
依托单位:
海外基金